Search results for: Multi-Indication Medicines
Filter search results
Multi-Criteria Decision Analysis to Value Orphan Medicines
1 May 2013
…Sussex, J., Rollet, P., Garau, M., Schmitt, C., Kent, A. and Hutchings, A., 2013. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value in Health, 16(8), pp.1163-1169….
Educational Webinar: Multiple Criteria Decision Analysis for Health Care Decision Making – Emerging Good Practices
28 February 2017
…Emerging Good Practices Task Force. Health care decisions are complex and involve confronting trade-offs between multiple, often conflicting, objectives. Using structured, explicit approaches to decisions involving multiple criteria can improve…
Multiple Sclerosis
1 May 1975
The unequal geographical distribution of multiple sclerosis is one of its most striking and potentially significant characteristics. The disease occurs with much greater frequency in temperate latitudes and it is…
Forecasting the UK Medicines Bill to 2014
7 November 2011
…a range of projections from it. To put medicines spending in context, Jon noted that approximately 14% of NHS operating costs in Scotland for 2009/10 were for medicines, compared to…
A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”
1 May 2018
This OHE Consulting Report reviews “Estimated costs of production and potential prices of medicines for the World Health Organization Essential Medicines List” (Hill et al., 2018) in which the authors…
Multi-criteria Decision Analysis (MCDA) to Support Healthcare Decisions: Opportunities, Challenges and Unresolved Questions
18 May 2017
…pilot study of multicriteria decision analysis for valuing orphan medicines. Value in Health, 16, 1163-9. Marsh K., et al., 2016. Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good…
Rare Disease Day 2022
28 February 2022
…Treatments for many rare conditions include the use of medicines; these medicines are referred to as orphan medicines. New innovative treatments are continually being developed, but there are a number…
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
…report was commissioned and funded by Sanofi. Share this: Download publication Biologics: Driving innovation in the treatment of multiple myeloma Biological medicines (biologics) have transformed the treatment landscape of multiple…
Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA
4 January 2019
…these issues. We note some of the implications for the development and use of PRO instruments, for their application in multi-country clinical trials, and for employing evidence from them in…